METHODS FOR SELECTIVE QUANTITATIVE ASSESSMENT OF A-BETA AGGREGATES Russian patent published in 2018 - IPC C07K16/18 G01N33/68 G01N33/53 

FIELD: biotechnology.

SUBSTANCE: method for quantitative assessment and characterisation of A-beta aggregates is described, comprising the following steps: a) entrainment molecules immobilisation on a substrate, b) application of a test sample and an internal standard to the substrate, c) addition of probes labeled for detection to label A-beta aggregates through specific binding to them, and d) determination of the number and size of labeled A-beta aggregates with spatial resolution in each case compared to the corresponding background, at that step b) can be carried out prior to step c). Also a kit for implementation of the described method, comprising a standard and one or more of the following: a glass substrate coated with a hydrophobic substance; an entrainment molecule; a probe; a substrate with the entrainment molecule; solutions; and a buffer, is presented. A method for determination of the efficacy of active substances and/or therapies for Alzheimer's disease treatment is provided, characterized by a) entrainment molecules immobilization on the substrate, b) test sample and internal standard application to the substrate, c) addition of probes labeled for detection, that label A-beta aggregates through specific binding to them, and d) determination of the number and size of labeled A-beta aggregates with spatial resolution in each case compared to the corresponding background. Step b) can be performed prior to step c), e) the results obtained on samples that are samples of a body fluid taken before or at various times after active substances administration and/or therapy are compared with the results obtained for control, which was not treated with the active substance and/or subjected to therapy, and based on the results obtained, active substances and/or therapies are selected, after which a reduction in the amount of A-beta aggregates was observed.

EFFECT: invention expands the arsenal of means intended for definition of efficiency of Alzheimer's disease treatment.

43 cl, 7 dwg, 3 ex